HRP20100334T1 - Terapeutska humanizirana antitijela protiv cd45-izoforma - Google Patents
Terapeutska humanizirana antitijela protiv cd45-izoforma Download PDFInfo
- Publication number
- HRP20100334T1 HRP20100334T1 HR20100334T HRP20100334T HRP20100334T1 HR P20100334 T1 HRP20100334 T1 HR P20100334T1 HR 20100334 T HR20100334 T HR 20100334T HR P20100334 T HRP20100334 T HR P20100334T HR P20100334 T1 HRP20100334 T1 HR P20100334T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- variable region
- chain
- antibody according
- humanized antibody
- Prior art date
Links
- 102000001708 Protein Isoforms Human genes 0.000 title 1
- 108010029485 Protein Isoforms Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/666,332 US20050069538A1 (en) | 2003-09-18 | 2003-09-18 | Therapeutic binding molecules |
| GB0414309A GB0414309D0 (en) | 2004-06-25 | 2004-06-25 | Organic compounds |
| PCT/EP2004/010471 WO2005026210A2 (en) | 2003-09-18 | 2004-09-17 | Therapeutic binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100334T1 true HRP20100334T1 (hr) | 2010-07-31 |
Family
ID=34315457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100334T HRP20100334T1 (hr) | 2003-09-18 | 2010-06-10 | Terapeutska humanizirana antitijela protiv cd45-izoforma |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1664122B1 (ru) |
| JP (1) | JP4762142B2 (ru) |
| KR (1) | KR20060079232A (ru) |
| AR (2) | AR045765A1 (ru) |
| AT (1) | ATE461219T1 (ru) |
| AU (1) | AU2004272289B2 (ru) |
| BR (1) | BRPI0414515A (ru) |
| CA (1) | CA2537217A1 (ru) |
| CY (1) | CY1110033T1 (ru) |
| DE (1) | DE602004026081D1 (ru) |
| DK (1) | DK1664122T3 (ru) |
| EC (1) | ECSP066432A (ru) |
| ES (1) | ES2341341T3 (ru) |
| HK (1) | HK1091844A1 (ru) |
| HR (1) | HRP20100334T1 (ru) |
| IL (1) | IL173820A0 (ru) |
| IS (1) | IS8397A (ru) |
| MA (1) | MA28041A1 (ru) |
| MY (1) | MY143963A (ru) |
| NO (1) | NO20061681L (ru) |
| NZ (1) | NZ545605A (ru) |
| PE (1) | PE20060019A1 (ru) |
| PL (1) | PL1664122T3 (ru) |
| PT (1) | PT1664122E (ru) |
| RU (1) | RU2386639C2 (ru) |
| SI (1) | SI1664122T1 (ru) |
| TN (1) | TNSN06087A1 (ru) |
| TW (1) | TW200521231A (ru) |
| WO (1) | WO2005026210A2 (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2502631A1 (en) | 2011-03-22 | 2012-09-26 | Medizinische Hochschule Hannover | Immune suppressor and its use |
| GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| CN105886609B (zh) * | 2015-02-17 | 2020-02-21 | 陈沛隆 | 药物不良反应风险评估方法及其装置 |
| CA2982115A1 (en) | 2015-04-06 | 2016-10-13 | President And Fellows Of Harvard College | Compositions and methods for non-myeloablative conditioning |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| JP2019522050A (ja) * | 2016-06-17 | 2019-08-08 | マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 細胞の枯渇のための組成物および方法 |
| JP2020522254A (ja) | 2017-05-31 | 2020-07-30 | エルスター セラピューティクス， インコーポレイテッド | 骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用 |
| WO2022079199A1 (en) | 2020-10-15 | 2022-04-21 | UCB Biopharma SRL | Binding molecules that multimerise cd45 |
| IL303270A (en) | 2020-12-21 | 2023-07-01 | Allogene Therapeutics Inc | The CD45–GATE vehicle activates a protease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6106834A (en) * | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
| GB0103389D0 (en) * | 2001-02-12 | 2001-03-28 | Novartis Ag | Organic compounds |
-
2004
- 2004-09-17 CA CA002537217A patent/CA2537217A1/en not_active Abandoned
- 2004-09-17 WO PCT/EP2004/010471 patent/WO2005026210A2/en active Application Filing
- 2004-09-17 BR BRPI0414515-1A patent/BRPI0414515A/pt not_active Application Discontinuation
- 2004-09-17 RU RU2006112598/13A patent/RU2386639C2/ru not_active IP Right Cessation
- 2004-09-17 TW TW093128255A patent/TW200521231A/zh unknown
- 2004-09-17 AU AU2004272289A patent/AU2004272289B2/en not_active Ceased
- 2004-09-17 KR KR1020067005352A patent/KR20060079232A/ko not_active Application Discontinuation
- 2004-09-17 ES ES04765363T patent/ES2341341T3/es active Active
- 2004-09-17 PT PT04765363T patent/PT1664122E/pt unknown
- 2004-09-17 NZ NZ545605A patent/NZ545605A/en not_active IP Right Cessation
- 2004-09-17 PL PL04765363T patent/PL1664122T3/pl unknown
- 2004-09-17 EP EP04765363A patent/EP1664122B1/en active Active
- 2004-09-17 JP JP2006526599A patent/JP4762142B2/ja not_active Expired - Fee Related
- 2004-09-17 AR ARP040103362A patent/AR045765A1/es active IP Right Grant
- 2004-09-17 MY MYPI20043795A patent/MY143963A/en unknown
- 2004-09-17 AT AT04765363T patent/ATE461219T1/de active
- 2004-09-17 DE DE602004026081T patent/DE602004026081D1/de active Active
- 2004-09-17 SI SI200431411T patent/SI1664122T1/sl unknown
- 2004-09-17 PE PE2004000909A patent/PE20060019A1/es not_active Application Discontinuation
- 2004-09-17 DK DK04765363.9T patent/DK1664122T3/da active
-
2006
- 2006-02-20 IL IL173820A patent/IL173820A0/en not_active IP Right Cessation
- 2006-03-14 MA MA28875A patent/MA28041A1/fr unknown
- 2006-03-17 EC EC2006006432A patent/ECSP066432A/es unknown
- 2006-03-17 TN TNP2006000087A patent/TNSN06087A1/en unknown
- 2006-04-03 IS IS8397A patent/IS8397A/is unknown
- 2006-04-12 NO NO20061681A patent/NO20061681L/no not_active Application Discontinuation
- 2006-11-09 HK HK06112334.4A patent/HK1091844A1/xx unknown
-
2010
- 2010-05-14 CY CY20101100424T patent/CY1110033T1/el unknown
- 2010-06-10 HR HR20100334T patent/HRP20100334T1/hr unknown
- 2010-12-14 AR ARP100104624A patent/AR079458A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100334T1 (hr) | Terapeutska humanizirana antitijela protiv cd45-izoforma | |
| CN102775493B (zh) | IL-1β结合抗体及其片段 | |
| HRP20171084T1 (hr) | Tihe fc-varijante protutijela anti-cd40 | |
| WO2005054273A3 (en) | Humanized antibodies against vascular endothelial growth factor | |
| HRP20161069T1 (hr) | Molekule antitijela koje vezuju il-17a i il-17f | |
| WO2006002177A3 (en) | Interferon alpha receptor 1 antibodies and their uses | |
| UA116614C2 (uk) | Антитіло до фактора d і його застосування | |
| AR035539A1 (es) | Moleculas de enlace capaces de enlazarse a isoformas cd45, polinucleotidos codificantes, un vector de expresion, un sistema de expresion, una celula huesped, el uso de dichas moleculas para la produccion de un medicamento y composiciones farmaceuticas. | |
| MY144612A (en) | Nogo-a neutralising immunoglobulins for treatment of neurological diseases | |
| RU2011110169A (ru) | Антитела против ccr2 | |
| WO2005110474A3 (en) | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
| EP1461081A4 (en) | ANTI-CD45RB ANTIBODY FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND TRANSPLANT ABLUSION | |
| WO2005059106A3 (en) | Interferon alpha antibodies and their uses | |
| ATE426615T1 (de) | Fur ein dem tumor-nekrose-faktor ahnlichen, apoptose-induzierenden ligandenrezeptor selektiven antikírper und dessen anwendungen | |
| UA93027C2 (ru) | Мутантное антитело, которое специфически связывается с cd40 | |
| JP2017518258A5 (ru) | ||
| Rangel-Santos et al. | Immunosuppresive role of principal toxin (crotoxin) of Crotalus durissus terrificus venom | |
| MX2015007831A (es) | Anticuerpos bmp-6. | |
| JP2021155456A (ja) | 黄色ブドウ球菌ロイコシジンの細胞毒性に関与する細胞因子：新規治療標的 | |
| JP2022141959A5 (ru) | ||
| Hakimi et al. | Development of Zenapax®: a humanized anti-Tac antibody | |
| CL2023002393A1 (es) | Anticuerpos anti-cd30l y usos de estos | |
| RU2017145662A (ru) | Моноклональные антитела и способы их применения | |
| SG162829A1 (en) | Humanised antibodies specific for nogo-a and pharmaceutical uses thereof | |
| HK1063601A1 (en) | Compositions and methods for treating hyperimmune response in the eye |